Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Aims: We conducted an updated network meta-analysis to evaluate and identify the optimal first-line treatment for advanced hepatocellular carcinoma (HCC) among all relevant interventional and targeted therapies.
Methods: We analyzed 16 phase 2 or 3 randomized controlled trials involving 9,482 patients with metastatic or unresectable HCC published between 2018 and 2024. The trials evaluated 11 systemic agents and 5 interventional treatments in combination with systemic therapy, using either sorafenib or lenvatinib as the control. The primary outcome was overall survival (OS), and secondary outcomes included progression-free survival (PFS) and grade 3-4 adverse events. Subgroup analyses were conducted to assess individual treatment efficacies in specific clinical settings.
Results: Transarterial chemoembolization (TACE) combined with lenvatinib provided the greatest improvement in OS over sorafenib, with a hazard ratio of 0.41 (95% confidence interval, 0.30-0.58), followed by sintilimab + IBI305 (0.57; 0.43-0.75), camrelizumab + rivoceranib (0.62; 0.48-0.80), atezolizumab + bevacizumab (0.66; 0.51-0.85), lenvatinib + pembrolizumab (0.77; 0.62-0.97), and tremelimumab + durvalumab (0.78; 0.64-0.95). These combinations, except for tremelimumab + durvalumab, also showed significantly superior PFS to sorafenib. TACE + lenvatinib was ranked first in OS analyses with the other current standard-of-care regimens (lenvatinib, atezolizumab + bevacizumab, and tremelimumab + durvalumab) as controls. TACE + lenvatinib, sintilimab + IBI305, and atezolizumab + bevacizumab demonstrated consistently significant extension of OS over sorafenib in subsets with portal invasion, extrahepatic metastasis, and hepatitis B. All immunotherapy-based combinations were significantly associated with a higher risk of adverse events than sorafenib.
Conclusions: For advanced HCC, our first-line analysis consistently scored TACE + lenvatinib the best for survival outcomes, followed by various immunotherapy-based combinations. However, the superior efficacy of TACE + lenvatinib should be interpreted with consideration of its derivation from a region with high hepatitis B virus prevalence.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240589 | PMC |
| http://dx.doi.org/10.1159/000546697 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predicting tumor response to TACE plus lenvatinib and PD-1 inhibitors for unresectable HCC: A multicenter observational study.
Eur J Radiol
September 2025
Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China. Electronic address:
Objectives: Preoperatively identifying patients with unresectable hepatocellular carcinoma (uHCC) who are likely to achieve an objective response to the treatment regimen of transarterial chemoembolization (TACE) plus lenvatinib and programmed death-1 inhibitors (TLP) remains challenging. We aimed to develop and validate a predictive model for tumor response to TLP treatment in patients with uHCC.
Materials And Methods: Patients with uHCC who received TLP treatment were divided into training (n = 107), internal validation (n = 46), and external validation (n = 52) cohorts.
Safety and clinical efficacy of immune checkpoint inhibitors in pediatric hepatocellular carcinoma: a case report and review of the literature.
Front Oncol
August 2025
Department of Oncology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Background: Pediatric hepatocellular carcinoma (HCC) is rare, with surgical resection and liver transplantation as primary treatments. No standard options exist for unresectable/metastatic disease. Although immune checkpoint inhibitors (ICIs) show efficacy in adults, their pediatric safety and efficacy remain unestablished.
View Article and Find Full Text PDFMyasthenia Gravis-Like Symptoms Following Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma: A Case Report.
Cancer Manag Res
August 2025
Hepatology and Gastroenterology Department, The Third Central Hospital of Tianjin, Tianjin, People's Republic of China.
We describe the case of an older male patient with hepatocellular carcinoma and a history of hepatitis B virus-related cirrhosis and type 2 diabetes mellitus. At 12 weeks after treatment with transcatheter arterial chemoembolization (TACE) combined with systemic therapy using lenvatinib and camrelizumab, the patient was found to have progressive disease, based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. He also exhibited symptoms such as left eyelid ptosis and limitations in inward, upward, and downward movements of the left eye.
View Article and Find Full Text PDFComparing neoadjuvant targeted therapy plus transarterial chemoembolization versus triple therapy including immunotherapy in hepatocellular carcinoma: a Chinese multicentre study.
Cancer Immunol Immunother
August 2025
Harbin Medical University Cancer Hospital, Harbin, 150000, China.
Background: Neoadjuvant therapy (NAT) is a promising strategy to improve long-term outcomes in hepatocellular carcinoma (HCC), particularly for patients with borderline resectable. Targeted therapy, transarterial chemoembolization (TACE), immunotherapy, and radiotherapy are all effective NAT strategies for HCC; however, the optimal NAT regimen for HCC remains undefined.
Methods: This multicentre retrospective study included 64 HCC patients who underwent NAT followed by surgical resection between 2020 and 2024 at four tertiary hospitals in China.
Donafenib lenvatinib combined with transarterial chemoembolization as initial therapy for unresectable hepatocellular carcinoma: a retrospective real-world study.
Quant Imaging Med Surg
August 2025
Department of Interventional Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Background: The combination of tyrosine kinase inhibitors (TKIs) with transarterial chemoembolization (TACE) holds promise for unresectable hepatocellular carcinoma (HCC). This study aimed to directly compare the efficacy and safety of donafenib (Dona)-TACE lenvatinib (LEN)-TACE as first-line therapies.
Methods: In this retrospective study, 93 unresectable HCC patients (49 Dona-TACE, 44 LEN-TACE; 93% hepatitis B virus-infected) treated between October 2020 and May 2023 were analyzed.